Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes

References

• Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000; 343: 905–14
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–7
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47
   PubMed Web of Science ®Google Scholar
• Johnston PG, Lenz HJ, Leichhman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407–12
   PubMed Web of Science ®Google Scholar
• Metzger R, Danenberg K, Leichman CG, Salonga D, Schwarz EL, Wadler S, et al. High basal level gene expression of thymidine phosphorylase(platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4: 2371–6
   PubMed Web of Science ®Google Scholar
• Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res 2000; 6: 1322–7
   Google Scholar
• Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003; 89: 1486–92
   PubMed Web of Science ®Google Scholar
• Grabowski P, Mann B, Mansmann U, Lövin N, Foss HD, Berger G, et al. Expression of SIALYL-Le(X) antigen defined by Mab AM-3 is an independent prognostic marker in colorectal carcinoma patients. Int J Cancer 2000; 15: 281–6
   Google Scholar
• Shimodaira K, Nakayama J, Nakamura N, Hasebe O, Katsuyama T, Fukuda M. Carcinoma-associated expression of core 2 beta-1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression. Cancer Res 1997; 57: 5201–6
   PubMedGoogle Scholar
• Baldus SE, Mönig SP, Hanisch FG, Zirbes TK, Flucke U, Oelert S, et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis (a) and sialyl-Lewis (x) antigens in colorectal adenocarcinoma. Histopathology 2002; 40: 440–9
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Mitoma J, Nakamura N, Katsuyama T, Nakayama J, Fukuda M. Induction of peripheral lymph node addressin in human gastric mucosa infected by Helicobacter pylori. Proc Natl Acad Sci USA 2004; 101: 17807–12
   Google Scholar
• Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, et al. Telomerase reverse transcriptase expression Is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4: 135–42
   PubMedGoogle Scholar
• Kornmann M, Schwabe W, Sander S, Kron M, Sträter J, Polat S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9: 4116–24
   PubMed Web of Science ®Google Scholar
• Kurebayashi J, Nishimura R, Tanaka K, Kohno K, Kurosumi M, Moriya T, et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer 2004; 11: 389–95
   PubMedGoogle Scholar
• Yamaguchi A, Kurosaka Y, Ishida T, Nishimura G, Kanno M, Kosaka T, et al. Clinical significance of tumor marker NCC-ST 439 in large bowel cancers. Dis Colon Rectum 1991; 34: 921–4
   PubMed Web of Science ®Google Scholar
• Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999; 5: 1996–9
   PubMed Web of Science ®Google Scholar
• Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metatatic colorectal cancer. Clin Cancer Res 2003; 9: 786–91
   PubMed Web of Science ®Google Scholar
• Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, et al. Increased expression of sialyl Lewis X antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993; 53: 3632–7
   PubMed Web of Science ®Google Scholar